Maryland Daily Record Maryland's trusted source for business and legal news
Peter Greenleaf, a respected figure in biotechnology circles with over 20 years of experience in the industry, has been named CEO of Waltham, Mass.-based Histogenics Corp.
Greenleaf’s most recent position was president of Gaithersburg-based MedImmune, the worldwide biologics arm of AstraZeneca.
He also was president of MedImmune Ventures, MedImmune’s venture capital arm, overseeing more than $300 million in investments in early-stage portfolio companies.
Greenleaf currently chairs the Maryland Venture Fund Authority.
Histogenics is a regenerative medicine company that combines cell therapy and tissue engineering technologies to develop innovative products primarily used for orthopedic tissue repair.
×
Enjoy This Free Article.
We Have 2 More For You.
All You Need To Do Is Register To Receive Your 2 Additional Free Articles.
